pimavanserin + antipsychotic

This is a combination treatment regimen consisting of **pimavanserin** used in conjunction with another **antipsychotic** (such as risperidone, aripiprazole, or olanzapine). Pimavanserin is a selective serotonin 5-HT2A receptor inverse agonist/antagonist, approved as monotherapy for Parkinson's disease psychosis. Combination therapy as adjunctive treatment with antipsychotics is being investigated, notably for predominant negative symptoms of schizophrenia in patients whose positive symptoms are controlled on antipsychotics. The combination aims to address the substantial unmet need for effective treatment of negative symptoms. In recent clinical studies, adjunctive pimavanserin plus antipsychotic demonstrated significant, clinically meaningful improvement in negative symptoms of schizophrenia versus antipsychotic monotherapy, with a favorable safety profile[1].